Refractory Multiple Myeloma- Pipeline Insight, 2024

Refractory Multiple Myeloma- Pipeline Insight, 2024

DelveInsight’s, “Refractory Multiple Myeloma- Pipeline Insight, 2024,”report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Refractory Multiple Myeloma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Refractory Multiple Myeloma Understanding

Refractory Multiple Myeloma: Overview

Multiple myeloma is a cancer that starts in a type of white blood cell called a plasma cell. It’s relatively rare, making up less than 2 percent, but it’s the most common type of plasma cell tumor, according to the CDC. The survival rate of multiple myeloma has improved in recent years, but initial treatment still isn’t effective at completely getting rid of the cancer in the vast majority. Myeloma is known as refractory if it’s resistant to treatment or becomes resistant during treatment. Refractory multiple myeloma is when myeloma doesn’t respond to treatment or stops responding to treatment. When patient has refractory multiple myeloma, patient may develop some of the same symptoms the patient had originally before treatment.

Patient may also develop other myeloma symptoms that the patient didn’t had before. Refractory multiple myeloma causes the same symptoms as multiple myeloma. These symptoms either don't go away or return after treatment. Bone pain is the most common symptom. In multiple myeloma, abnormal plasma cells multiply in the bone marrow -- the soft, squishy tissue in the center of bones where new blood cells are made. Experts don't know what causes multiple myeloma, or why it is refractory in some people. They think gene changes may make the cancer more resistant to treatment. Doctors prescribe three main types of medications for refractory multiple myeloma: Proteasome inhibitors, such as carfilzomib (Kyprolis) or ixazomib (Ninlaro), which slow the multiplying of myeloma cells, Immunomodulatory drugs, such as thalidomide (Thalomid) and lenalidomide (Revlimid). They block the pathways that help multiple myeloma grow. Monoclonal antibodies such as daratumumab (Darzalex) and elotuzumab (Empliciti). They are human-made versions of proteins that body makes.

They attack proteins on the surface of myeloma cells to kill them directly, and help immune system fight them. People with refractory multiple myeloma sometimes take two or three of these medicines at a time, along with a steroid medicine to kill more myeloma cells. Selinexor (Xpovio)-This is a new kind of medication called a nuclear export inhibitor. It blocks a protein that helps myeloma cells stay alive. Researchers are studying new treatments for refractory multiple myeloma in clinical trials. The outlook for refractory multiple myeloma is generally poorer than myeloma that responds to initial treatment. However, advances in treatment mean that people with refractory multiple myeloma now have many treatment options available.

""Refractory Multiple Myeloma- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Refractory Multiple Myeloma pipeline landscape is provided which includes the disease overview and Refractory Multiple Myeloma treatment guidelines. The assessment part of the report embraces, in depth Refractory Multiple Myeloma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Refractory Multiple Myeloma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Refractory Multiple Myeloma R&D. The therapies under development are focused on novel approaches to treat/improve Refractory Multiple Myeloma.

Refractory Multiple Myeloma Emerging Drugs Chapters

This segment of the Refractory Multiple Myeloma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Refractory Multiple Myeloma Emerging Drugs

• Felzartamab: MorphoSys

Felzartamab is an investigational human monoclonal antibody developed using MorphoSys' HuCAL® antibody technology. The antibody targets against CD38 present on the surface of multiple myeloma cells. The drug candidate uses antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) for tumor cell killing. Currently it is in Phase III stage of clinical trial evaluation to treat Refractory Multiple Myeloma.

• RAPA-201: Rapa Therapeutics

RAPA-201 It is a type of autologous cell therapy. The drug candidate is gene transference, T lymphocyte replacements and work on the same mechanism of action. Currently the drug is being evaluated in Phase II for the treatment of Refractory Multiple Myeloma.

• PHE885: Novartis

PHE885 is an autologous, fully human, BCMA-directed CAR T-cell therapy being developed by Novartis for the treatment of refractory multiple myeloma. It is administered through intravenous route. The therapeutic candidate consists of autologous T cells that are genetically modified to express chimeric antigen receptor that targets BCMA (B-cell maturation antigen). Currently it is in Phase II stage of clinical trials.

• ABBV 453: AbbVie

ABBV-453 is an investigational drug candidate being developed for the treatment of relapsed or refractory multiple myeloma. It is administered through oral route as tablet formulation. It acts by targeting B-cell lymphoma 2 (BCL-2) protein. Currently the drug is in Phase I stage of clinical trials.

Further product details are provided in the report…….

Refractory Multiple Myeloma: Therapeutic Assessment

This segment of the report provides insights about the different Refractory Multiple Myeloma drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Multiple Myeloma

There are approx. 80+ key companies which are developing the therapies for Refractory Multiple Myeloma. The companies which have their Refractory Multiple Myeloma drug candidates in the most advanced stage, i.e. phase II include, MorphoSys

• Phases

Delve Insight’s report covers around 80+ products under different phases of clinical development like

• Late stage products (Phase II)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Refractory Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Refractory Multiple Myeloma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III II, I, preclinical and discovery stage. It also analyses Refractory Multiple Myeloma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Refractory Multiple Myeloma drugs.

Refractory Multiple Myeloma Report Insights

• Refractory Multiple Myeloma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Refractory Multiple Myeloma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Refractory Multiple Myeloma drugs?
• How many Refractory Multiple Myeloma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Refractory multiple myeloma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Refractory Multiple Myeloma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Refractory Multiple Myeloma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• MorphoSys
• Janssen Research & Development, LLC
• Rapa Therapeutics
• Novartis
• AbbVie
• MiNK Therapeutics
• AbbVie
• Amgen
• Gracell Biopharmaceuticals, Inc.
• Zhejiang ACEA Pharmaceutical Co. Ltd.
• Allogene Therapeutics
• Beijing InnoCare Pharma Tech Co., Ltd.
• Takeda
• Novartis Pharmaceuticals

Key Products

• Felzartamab
• Talquetamab
• RAPA-201
• PHE885
• ABBV 453
• AGENT 797
• Venetoclax
• Dexamethasone
• GC012F
• STI-6129
• ABT-199
• ALLO-605
• ICP-490
• TAK-981
• AUY922